Citation Impact
Citing Papers
Omalizumab for asthma in adults and children
2014
Neuroplasticity – Exercise-Induced Response of Peripheral Brain-Derived Neurotrophic Factor
2010
The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation
2005
Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-Galactose
2008 Standout
Predicting Response to Omalizumab, an Anti-IgE Antibody, in Patients With Allergic Asthma
2004
Benefits of omalizumab as add‐on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE
2004
Pulmonary fibrosis: pathogenesis, etiology and regulation
2009 Standout
Update on optimal use of omalizumab in management of asthma
2011
IgE and mast cells in allergic disease
2012 Standout
Asthma
2017 Standout
Nerve Growth Factor: Neurotrophin or Cytokine?
2003
The development of allergic inflammation
2008 StandoutNature
Low Brain-Derived Neurotrophic Factor (BDNF) levels in serum of depressed patients probably results from lowered platelet BDNF release unrelated to platelet reactivity
2005
Antibodies as therapeutic agents: vive la renaissance!
2003
Small-molecule inhibitors of protein–protein interactions: progressing towards the dream
2004 Standout
The role of “anti-inflammatory” cytokines in axon regeneration
2012
Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes
2007 Standout
The effects of acute exercise on cognitive performance: A meta-analysis
2012 Standout
mRNA transcript therapy
2014 StandoutNobel
Global strategy for asthma management and prevention: GINA executive summary
2007 Standout
Remodeling in Asthma
2009
Major Depressive Disorder
2008 Standout
Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial
2012 Standout
Helminth parasites – masters of regulation
2004 Standout
Alternate day calorie restriction improves clinical findings and reduces markers of oxidative stress and inflammation in overweight adults with moderate asthma
2006
Airway Mucus Function and Dysfunction
2010 Standout
The ketone metabolite β-hydroxybutyrate blocks NLRP3 inflammasome–mediated inflammatory disease
2015 Standout
Impact of omalizumab on quality-of-life outcomes in patients with moderate-to-severe allergic asthma
2006
Allergic rhinitis: An update on disease, present treatments and future prospects
2011
Anti‐immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti‐inflammatory activity and clinical efficacy
2005
Effects of Treatment with Anti-immunoglobulin E Antibody Omalizumab on Airway Inflammation in Allergic Asthma
2004
Fasting and cancer treatment in humans: A case series report
2009 Standout
Dissemination and publication of research findings: an updated review of related biases
2010 Standout
Mast Cells Promote Airway Smooth Muscle Cell Differentiation via Autocrine Up-Regulation of TGF-β1
2008
Design, Synthesis, and Inhibitory Activity of Potent, Photoswitchable Mast Cell Activation Inhibitors
2013 StandoutNobel
Roles of NF-κB in Cancer and Inflammatory Diseases and Their Therapeutic Approaches
2016 Standout
Omalizumab for treatment of allergic rhinitis
2013
Works of G. Hanf being referenced
Differential activation of dendritic cells by nerve growth factor and brain‐derived neurotrophic factor
2007
Immunological and Clinical Changes in Allergic Asthmatics following Treatment with Omalizumab
2003
The production, storage and release of the neurotrophins nerve growth factor, brain‐derived neurotrophic factor and neurotrophin‐3 by human peripheral eosinophils in allergics and non‐allergics
2003
Omalizumab inhibits allergen challenge-induced nasal response
2004
The influence of inhalative corticosteroids on circulating Nerve Growth Factor, Brain‐Derived Neurotrophic Factor and Neurotrophin‐3 in allergic asthmatics
2001
The anti-IgE antibody omalizumab improves asthma-related quality of life in patients with allergic asthma
2002
Monocytes of allergics and non-allergics produce, store and release the neurotrophins NGF, BDNF and NT-3
2004
Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma
2006
Omalizumab (rhuMAb-E25) induziert Apoptose in eosinophilen Granulozyten bei allergischen Atshmatikern
2005